An open-label, multicenter study to assess the efficacy of switching to a combination tablet ezetimibe/simvastatin 10mg/40mg, compared to doubling the dose of statin in patients hospitalized with a coronary event

Trial Profile

An open-label, multicenter study to assess the efficacy of switching to a combination tablet ezetimibe/simvastatin 10mg/40mg, compared to doubling the dose of statin in patients hospitalized with a coronary event

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms INFORCE
  • Sponsors Merck & Co
  • Most Recent Events

    • 13 Oct 2012 Planned number of patients changed from 450 to 490.
    • 07 Jun 2010 Data from this trial was used in an economic analysis published in Value in Health.
    • 24 Oct 2009 Data from the trial was used in an economic analysis presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top